Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
NCT ID: NCT00389948
Last Updated: 2007-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
576 participants
INTERVENTIONAL
2006-06-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lanzoprazole
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Having heartburn that responds to heartburn medication.
3. Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.
Exclusion Criteria
2. Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Consultants Inc.
Hoover, Alabama, United States
Huntsville, Alabama, United States
Radiant Research
Sierra Vista, Arizona, United States
California Bio Medical Research Institute
Los Angeles, California, United States
Allergy Medical Group of North Area
Roseville, California, United States
Eastern Research
Hialeah, Florida, United States
Health Awareness Inc.
Jupiter, Florida, United States
Miami Research Associates
Miami, Florida, United States
Radiant Research
Atlanta, Georgia, United States
Radiant Research
Atlanta, Georgia, United States
Evansville, Indiana, United States
Clinical Associates
Reisterstown, Maryland, United States
Medex Healthcare Research, Inc.
St Louis, Missouri, United States
Meridian Clinical Research LLC
Omaha, Nebraska, United States
William W. Anderson M.D. P.C.
Rio Rancho, New Mexico, United States
IRSI
Port Chester, New York, United States
Crescent Medical Research
Salisbury, North Carolina, United States
Micheal Alexander, DO
Columbus, Ohio, United States
New Hope Research of Oregon
Portland, Oregon, United States
Preferred Primary Care Physicians
Carnegie, Pennsylvania, United States
Advanced Therapeutics, Inc
Johnson City, Tennessee, United States
Nashville Medical Research
Nashville, Tennessee, United States
Medical Edge Healthcare Group, P.A.
Dallas, Texas, United States
Benchmark Research
Fort Worth, Texas, United States
Benchmark Research
San Angelo, Texas, United States
Commonwealth Clinical Research Specialist
Richmond, Virginia, United States
National Clinical Research Inc.
Richmond, Virginia, United States
Radiant Research
Lakewood, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRSW-GN-301
Identifier Type: -
Identifier Source: org_study_id